TriAgenics, the pioneer of fully guided tooth bud ablation, has announced the grant of four additional European patents, further establishing the company’s global IP position for a novel technology designed to prevent third molar formation. Germany, France, Italy, and the United Kingdom are the latest European countries to grant a patent for TriAgenics’ ablation probe system.
TriAgenics’ patented micro-ablation technology is the cornerstone behind Zero3 TBA, a preventive-care treatment for children ages 6–12. The treatment prevents the formation of third molars through the application of low-level, CT-guided microwave energy. This new dental modality is based on microwave ablation techniques commonly used in the medical field. TriAgenics plans to introduce Zero3 TBA to the U.S. dental market in 2025, following clearance from the U.S. Food and Drug Administration.
Following FDA clearance, dentists will send patient CBCT and intraoral scans to TriAgenics, which will fabricate custom Zero3 kits and ship them to dentists to perform the one-minute treatment using TriAgenics’ proprietary ablation technology.
TriAgenics believes the economic impact of Zero3 TBA treatment will be massive. Total expenditures associated with extracting third molars and correcting related problems are estimated to be nearly $5 billion in the U.S. alone.
TriAgenics estimates its total addressable market will be greater than $2.5 billion annually when Zero3 TBA treatment becomes the new standard of care in the U.S.
About TriAgenics
TriAgenics is a disruptive oral healthcare company that has pioneered the development of a one-minute treatment designed to prevent third molars from ever forming. Based on extensive animal trials, TriAgenics’ Zero3 TBA system is expected to eliminate all pain and complications normally associated with third molar extraction. TriAgenics’ mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school.
Source: www.triagenics.com
News 09 October 2025
TriAgenics, Inc., a privately held company pioneering a non-surgical approach to third molar (wisdom tooth) prevention, today announced that it expanded its Series B-1 funding round in response to...
News 05 May 2025
TriAgenics, Inc., pioneer of Zero3 TBA, a fully guided tooth bud ablation system designed to prevent third molar formation, announced that David Thrower has been named president and CEO.
News 08 May 2026
Maria Gutierrez in Yorba Linda, California, has added the DEXIS Orthopantomograph OP 3D EX cone beam computed tomography (CBCT) system to its practice.
News 08 May 2026
35-year healthcare veteran who scaled dental and Medicaid programs to over $1 billion in revenue joins as LightSpun enters critical growth phase on the heels of NationsBenefits and
News 24 April 2026
35-year healthcare veteran who scaled dental and Medicaid programs to over $1 billion in revenue joins as LightSpun enters critical growth phase on the heels of
Edra Professional Books 06 June 2026
Understanding Dental Insurance: A Practical Reference for Dental Professionals
Understanding Dental Insurance is an Edra professional dentistry reference focused on clinical practice, education and treatment planning.
New initiative invites dentists to experience DEXIS’ most advanced AI yet, built on scale, speed, and clinical trust.
News 05 June 2026
(Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/C
News 05 June 2026
(Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected Will
As the University of Colorado School of Dental Medicine celebrates the graduating DDS Class of 2025, we are proud to recognize the students and faculty members whose exceptional de